中文 | English

Breakthrough & Progress of Non-small cell lung cancer drug , are you ready?

Event details

DATE
Tuesday, Sep 26, 2023

VENUE
Online Webex / Zoom

TIME
10:00 – 11:00 Berlin time (CET)
16:00 – 17:00 Beijing time (GMT+8)

RSVP
This is a complimentary event
VIP tickets priority for Lingmed current clients
Please RSVP by Sep 25, 2023
PRESENTERS
Lingling Cao, CEO & Founder
Zhang Ran, Medical advisor


REGISTER
+86 21 5386 3003
BD@lingmed.net

Agenda

CET 10:00 - 10:30 Breakthrough & Progress of Non-small cell lung cancer drug
by Zhang Ran  (Chinese)
CET 10:30 - 10:35Linkedbio services & projects introduction    by Lingling Cao  (English)
CET 10:35 - 10:55An innovative biotech roadshow by Guest speaker   (English)
CET 10:55 – 11:00Q&A (English & Chinese)

Presenters

Zhang Ran
Medical advisor
China Pharmaceutical University master
HealthShare Management and Consulting Co., Ltd Co-founder
20 years of experience in new drug development. Engaged in new drug research and development in Yangtze River Pharmaceutical Group、Beijing Kawin Technology Share-Holding Co., Ltd.、Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.
Co-founded HealthShare in 2016. Serve a number of listed pharmaceutical enterprises. Mainly engaged in research and development pipeline strategic planning, new drug project evaluation, research and development management.

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany

Register
©Copyright 2013 - Lingmed Limited